BioSpace News Archive

9 Meters Biopharma, Inc. announced an update on its late stage pipeline products vurolenatide, a proprietary long-acting glucagon-like peptide agonist in a Phase 2 trial for adults with short bowel syndrome, and larazotide, a gut-selective tight junction modulator in a Phase 3 trial for celiac disease.

Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Rob Ross, M.D., chief executive officer, will participate in the “Novel Immuno-Oncology” panel discussion at Cowen’s 42nd Annual Health Care Conference.

Merus N.V., a clinical-stage oncology company developing innovative, full-length multispecific antibodies, announced financial results for the fourth quarter and full year ended December 31, 2021 and provided a business update.

Lucira Health, Inc., a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, announced that the company will report fourth quarter 2021 financial results on, Thursday, March 10, 2022.

Karyopharm Therapeutics Inc. announced that the Company approved the grant of stock options to purchase an aggregate of 168,500 shares of Karyopharm’s common stock and an aggregate of 112,200 restricted stock units to nine newly-hired employees.

Metagenomi announced that Brian C. Thomas, PhD, Founder and CEO of Metagenomi, and Chris Brown, PhD, Senior Director of Discovery, will present at the virtual Chardan Metagenomics and Microbiome Medicines Summit on Tuesday, March 1, 2022.

Affinivax, Inc. (“Affinivax”) and Astellas Pharma Inc. (“Astellas”) today announced that they have entered into an agreement whereby Affinivax has reacquired the exclusive worldwide rights to ASP3772, a novel vaccine candidate targeting Streptococcus pneumoniae.

Taro Pharmaceutical Industries Ltd. announced the completion of its acquisition of Alchemee, formerly The Proactiv Company, from Galderma.